Levothyroxine

Limits on what this shows

• Key negative/null findings: None of the sources located describe levothyroxine at therapeutic replacement dosing as damaging or overburdening mitochondria; the concern in the literature is specifically supratherapeutic/thyrotoxic dosing, which manifests as clinical outcomes (tachyarrhythmia, thyrotoxic myopathy) rather than a measured mitochondrial-injury marker, and per this platform's rules those clinical outcomes are not filed here as a nutrient-style mitochondrial deficiency.
• At-risk subgroups: Not applicable as a depletion risk; over-replacement/thyrotoxic dosing is a distinct, dose-related pharmacologic risk already captured in cardiovascular and bone entries elsewhere in the literature, outside this dossier's classical-nutrient scope.
• Counter-evidence on record: None identified; the mechanism is restorative by design in the treated (hypothyroid) population.

Regulatory status

Not addressed in FDA labeling as a mitochondrial claim.

Population evidence

Tier B mechanistic/pharmacology literature, confirmed via Crossref: Weitzel, Iwen & Seitz, "Regulation of Mitochondrial Biogenesis by Thyroid Hormone," Experimental Physiology 2003; Marin-Garcia, "Thyroid hormone and myocardial mitochondrial biogenesis," Vascular Pharmacology 2010; Mutvei, Husman, Andersson & Nelson, "Thyroid hormone and not growth hormone is the principle regulator of mammalian mitochondrial biogenesis," Acta Endocrinologica 1989. These establish thyroid hormone generally (not levothyroxine-dosed human cohorts specifically) as the principal driver of this pathway.

Mechanism

Named: T3 acts on nuclear thyroid hormone receptors to upregulate transcription of nuclear-encoded mitochondrial genes and coactivators (e.g., PGC-1 family pathway), increasing mitochondrial mass and respiratory capacity.

Counter-evidence held on record

This is the drug's intended therapeutic mechanism restoring normal mitochondrial activity in a hypothyroid patient, not a mitochondrial-burden deficiency. It must never be marketed as levothyroxine harming mitochondria.

Limits on what this shows

• Key negative/null findings: No null or contradicting levothyroxine-specific human trial was located because no levothyroxine-specific human trial on this topic was located at all in the channels this review could access.
• At-risk subgroups: Cannot be specified with confidence given the mechanism-only evidence base.
• Counter-evidence on record: None identified, for the same reason.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Tapbergenov, Sovetov, Bekbosynova & Bolysbekova, "Glutathione Redox System, Immune Status, Antioxidant Enzymes and Metabolism of Purine Nucleotides in Hypothyroidism," Biomeditsinskaya Khimiya 2015 (Tier B/C: experimental/animal hypothyroidism model, studies the untreated disease state, not levothyroxine treatment, and this review could not verify whether levothyroxine correction was tested within the same study).

Mechanism

Named but not drug-specific: thyroid hormone raises basal metabolic rate and mitochondrial oxidative flux (see Mitochondrial burden and ATP production entries), which is a plausible substrate for altered reactive-oxygen-species generation at high tissue T3 exposure; hypothyroidism itself is separately associated with altered baseline antioxidant enzyme activity in animal models.

Counter-evidence held on record

Tooling limitation disclosed: PubMed, PubMed Central, the Europe PMC REST API, and the Semantic Scholar API were persistently blocked or rate-limited during this specific search (bot-verification pages and repeated HTTP 429 responses across multiple query phrasings and hosts), and this session's web-search tool was exhausted before this category could be searched by that route. This is graded yellow on the mechanistic literature actually retrieved, not ungraded, because that literature does meet the Tier B bar; a future revision should re-run this category once those channels are available, since a levothyroxine-specific human oxidative-stress trial may well exist and simply was not reachable here.

Limits on what this shows

• Key negative/null findings: Effect is reversible on discontinuation of concurrent dosing and preventable by dose separation; liquid levothyroxine formulations show attenuated interaction with iron in small pharmacokinetic studies, though this does not eliminate the need for separation with standard tablets.
• At-risk subgroups: Patients on iron supplementation for anemia (including pregnant patients, who commonly take both), and patients who are not counseled on timing; real-world survey data found roughly 15% of hypothyroid patients report taking iron close in time to their levothyroxine dose.
• Counter-evidence on record: No credible study contradicts the direction of this interaction; the open question in the literature is magnitude by formulation (tablet vs. soft-gel vs. liquid), not existence.

Regulatory status

FDA label instructs administering levothyroxine at least 4 hours apart from ferrous sulfate/fumarate and other iron salts.

Population evidence

Campbell, Hasinoff, Stalts, Rao & Wong (Ann Intern Med, 1992): 14 hypothyroid patients given ferrous sulfate with their levothyroxine; TSH rose in 11 of 14, and 9 developed signs/symptoms of hypothyroidism, resolving after separation. A 2021 systematic review of 63 studies (Wiesner et al., Pharmaceuticals) confirms iron as a consistently identified absorption-reducing co-ingestant across multiple case reports and cohort data, alongside case reports of ferrous-sulfate-induced increased thyroxine requirement in individual patients.

Mechanism

Named: chelation of the drug's iodinated phenolic structure by iron cations into an insoluble complex in the gut lumen.

Counter-evidence held on record

This is not levothyroxine depleting iron and it is not a reason to avoid iron therapy. The fix is timing: separate iron supplements or iron-fortified products from levothyroxine dosing by at least 4 hours.

Limits on what this shows

• Why no grade: Dual condition met: no verifiable Tier B or C evidence of a levothyroxine-specific effect on copper or ceruloplasmin status was found, and no circulating consumer claim about levothyroxine and copper was found in this review.

Context to disclose / tooling note

A Crossref search located a title, "To Study Serum Ceruloplasmin Level in Early Diagnosed Patients with Subclinical Hypothyroidism" (Kaushik & Bairwa, International Journal of Science and Research, 2021), which appears to address ceruloplasmin in the untreated disease state rather than levothyroxine treatment; its full text returned a 404 error through available tooling and could not be verified in enough detail to cite as supporting evidence at any tier. This is disclosed as a tooling limitation: a future revision with working access to Europe PMC, Semantic Scholar, or the publisher's own site should re-check this specific source and search more broadly before this entry is finalized as a true long-term gap.

Limits on what this shows

• Key negative/null findings: The review notes that the strength of the microbiome-specific evidence is less direct than for H. pylori or celiac disease (an anatomic/mucosal mechanism); it is described as a plausible contributing mechanism rather than a fully quantified independent effect.
• At-risk subgroups: Patients with lactose intolerance, small intestinal bacterial overgrowth, prior bariatric surgery, or other conditions altering gut flora or transit.
• Counter-evidence on record: This review found no evidence, in the sources it could access, that levothyroxine itself changes gut microbiome composition or diversity (the forward direction of this category as usually framed). The graded claim here is limited to the reverse direction: microbiome status affecting the drug.

Regulatory status

Not addressed in FDA labeling; drawn from a peer-reviewed synthesis.

Population evidence

Virili, Antonelli, Santaguida, Benvenga & Centanni, "Gastrointestinal Malabsorption of Thyroxine," Endocrine Reviews 2019;40(1):118-136 (a Tier A systematic synthesis with levothyroxine as the specific drug studied throughout). Reports that intestinal microbiota assist deconjugation of T4 conjugates via bacterial sulfatase and glucuronidase activity, enabling hepatic reuptake; conditions altering gut flora, including lactose intolerance (associated with 31% increased T4 dose requirement vs. controls) and small intestinal bacterial overgrowth, are linked to increased levothyroxine dose requirements. Helicobacter pylori gastritis increases T4 requirement by roughly one-third; celiac disease (present in 2-5% of hypothyroid patients) increases requirement, reversible on a gluten-free diet.

Mechanism

Named: bacterial sulfatase/glucuronidase-mediated deconjugation enabling enterohepatic recycling of T4; disruption of the responsible flora (dysbiosis, SIBO, lactose intolerance-associated flora shifts) reduces this recycling and lowers effective bioavailability.

Counter-evidence held on record

This is not levothyroxine disrupting the gut microbiome. It is gut flora status affecting how much levothyroxine gets absorbed. Probiotic supplementation for this purpose is not supported by data found in this review and is not recommended here.

Limits on what this shows

• Key negative/null findings: The iron-alone arm in Cinemre 2009 still showed some hemoglobin improvement (0.4 g/dL), confirming iron therapy has independent effect; the levothyroxine contribution is additive/synergistic rather than iron therapy being ineffective without it.
• At-risk subgroups: Patients with concurrent iron-deficiency anemia and subclinical hypothyroidism specifically; this finding does not generalize to euthyroid patients or to overt hypothyroidism without accompanying anemia.
• Counter-evidence on record: This is a single population (iron-deficient, subclinically hypothyroid); no data reviewed here show a hemoglobin/oxygen-delivery benefit of levothyroxine in euthyroid or non-anemic patients, and this entry should not be read as levothyroxine broadly improving oxygen delivery outside this bounded population.

Regulatory status

Not addressed in FDA labeling; drawn from a randomized controlled trial.

Population evidence

Cinemre, Bilir, Gokosmanoglu & Bahcebasi, J Clin Endocrinol Metab 2009;94(1):151-156 (PMID 18984662): randomized, double-blind, controlled trial, N=51 patients with concurrent iron-deficiency anemia and subclinical hypothyroidism, randomized to oral iron alone (240 mg/day) vs. iron plus levothyroxine (75 mcg/day). Mean hemoglobin rose 0.4 g/dL in the iron-alone group vs. 1.9 g/dL in the iron-plus-levothyroxine group. A related trial (Ravanbod, Asadipooya, Kalantarhormozi, Nabipour & Omrani, "Treatment of Iron-deficiency Anemia in Patients with Subclinical Hypothyroidism," Am J Med 2013;126(5):420-424) independently studied the same comparison; this review confirmed the citation and journal record but could not retrieve its full abstract text through available tooling, so its specific effect sizes are not restated here.

Mechanism

Named, plausible: subclinical hypothyroidism is independently associated with impaired erythropoiesis and reduced intestinal iron absorption/utilization; correcting the thyroid state with levothyroxine restores a more normal hematologic response to iron repletion.

Counter-evidence held on record

This is a corrective/protective finding in a specific bounded population, not a general energy or oxygen-delivery claim for levothyroxine users, and not a reason to start levothyroxine for anemia without a documented thyroid indication.

Limits on what this shows

• Key negative/null findings: No data located in this review describe levothyroxine at therapeutic dosing as impairing ATP production; the foundational literature is decades old, animal/tissue-based, and has not been challenged by more recent contradicting data found in this search.
• At-risk subgroups: Not applicable as a depletion risk.
• Counter-evidence on record: None identified.

Regulatory status

Not addressed in FDA labeling as an ATP-specific claim; low energy/fatigue is listed as a hypothyroidism symptom the drug is intended to resolve.

Population evidence

Tier B foundational pharmacology, confirmed via Crossref: Primack, Tapley & Buchanan, "Thyroid Hormone Stimulation of Mitochondrial Protein Synthesis Supported by an ATP Generating System," Endocrinology 1972, alongside the mitochondrial-biogenesis literature cited in the entry above (Weitzel 2003, Marin-Garcia 2010, Mutvei 1989), which this review discloses shares the same underlying mechanistic source base (see Overlap map).

Mechanism

Named: increased mitochondrial mass and respiratory chain activity under T3 stimulation increases the cell's oxidative ATP-generating capacity, consistent with thyroid hormone's role in raising basal metabolic rate.

Counter-evidence held on record

This is restorative pharmacology in a hypothyroid patient, not evidence that levothyroxine depletes cellular energy or ATP. Persistent fatigue on levothyroxine should prompt a dose/TSH review with a prescriber, not a supplement recommendation from this entry.